Home Drug Development Pipeline

Pipeline

Debiopharm International’s projects cover all molecule type proteins,
peptides, small molecules

Discovery Preclinical Phase I Phase II Phase III
Debio 1143, Head & Neck Cancer
Head & Neck Cancer
IAP antagonist
btd
Debio 1143*, NSCLC
NSCLC
IAP antagonist
Debio 1143**, Selected solid tumors
Selected solid tumors
IAP antagonist
Debio 1143***, Selected solid tumors
Selected solid tumors
IAP antagonist
naratuximab emtansine (Debio 1562), Diffuse large B-cell lymphoma
Diffuse large B-cell lymphoma
Anti-CD37 ADC
odd
Debio 1347, Oncology
Oncology
FGFR1,2,3 inhibitor
odd/ft
Debio 1347****, Metastatic breast cancer
Metastatic breast cancer
FGFR 1, 2, 3 inhibitor
Debio 8200**, Advanced melanoma resistant
Advanced melanoma resistant
GnRH
Debio 1124, Medullary thyroid cancer
Medullary thyroid cancer
Minigastrin-Lu177
Debio 0123, Oncology
Oncology
Wee1 kinase inhibitor
Debio 0228, Oncology
Oncology
CAIX-targeted radiotherapy
afabicin (Debio 1450), ABSSSI
ABSSSI
FabI inhibitor
ft/qidp
afabicin (Debio 1450), Bone & joint infections
Bone & joint infections
FabI inhibitor
odd/ft/qidp
Debio 1561, Infectious diseases
Infectious diseases
Sample prep. Technology
Debio 025, GI disorders
GI disorders
Cyclophilin inhibitor
Debio 1453, N. gonorrhoeae
N. gonorrhoeae
Fabl inhibitor
carb-x
Debio 1454/S, A. baumannii
A. baumannii
Fabl inhibitor
carb-x
Debio 1454/M, Undisclosed
Undisclosed
Fabl inhibitor
Debio 4028, Infectious diseases
Infectious diseases
IAP antagonist
*in combination with avelumab
**in combination with nivolumab
***in combination with pembrolizumab
****in combination with fulvestrant
odd
Orphan Drug Designation
ft
Fast-Track
qidp
Qualified Infectious Disease Product
btd
Breakthrough Therapy Designation
carb-x
CARB-X
Infectious disease
Oncology

Our commercialized products

Clinical trials

Debiopharm’s vision of healthcare is not limited to making new medicines available. We strongly believe you can be an actor in your own medical care.

More about clinical trials